Skip to main content
. Author manuscript; available in PMC: 2013 Nov 19.
Published in final edited form as: Vaccine. 2012 Oct 4;30(49):10.1016/j.vaccine.2012.09.057. doi: 10.1016/j.vaccine.2012.09.057

Table 1.

Prophylactic vaccination with Vaxfectin® pDNA prevents primary and recurrent disease in the guinea pig model.

Group Primary disease
Recurrent disease
Incidence Severitya Incidence Frequencyb
Naïve 15/15 9.3 ± 4.7 10/11 5.5 ± 3.9
Vaxfectin®-gD2 0/15c 0 ± 0 0/15c 0 ± 0
Vaxfectin®-gD2/UL46/UL47 0/15c 0 ± 0 0/15c 0 ± 0
a

Primary disease severity defined as cumulative daily lesion score, mean ± SD.

b

Recurrent disease frequency defined as recurrent lesion days between days 15–63 post-inoculation, mean ± SD.

c

p<0.001 compared to control, Fisher’s exact test